Minaris Advanced Therapies Overview

A leading global partner for cell and gene therapy development and manufacturing provides unmatched scale, expertise, and infrastructure to accelerate advanced therapies from discovery to delivery. With decades of experience and a proven commercial track record, services span process development, analytical development, clinical and commercial manufacturing, and a full suite of GMP testing. Capabilities include plasmid and viral vector design and production, cell line development, and IND-enabling studies, ensuring seamless support from early-stage research through BLA submission.

The organization operates across five sites on three continents, featuring more than 60 clean rooms and over 650,000 square feet of purpose-built facilities. Expertise covers a wide range of modalities, including CAR-T, NK/CAR-NK, TCR-T, TIL/MIL, iPSC, MSC, and viral vectors such as AAV, LVV, HSV, and adenovirus. Comprehensive testing services include lot release, cell line characterization, potency assays, stability assessments, and viral clearance, all performed under rigorous quality and regulatory standards.

With over 20 successful global health authority inspections and thousands of GMP batches released, this partner combines innovation with reliability to enable therapeutic developers to scale globally while reducing risk and accelerating timelines.